CYCC Cyclacel Pharmaceuticals Inc.

0.47
+0.01  (+1%)
Previous Close 0.46
Open 0.46
Price To Book 0.46
Market Cap 7,999,708
Shares 17,199,974
Volume 222,229
Short Ratio
Av. Daily Volume 97,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data released February 23, 2017 that primary endpoint was not met. Complete remission (CR) improvement noted - secondary endpoint.
Sapacitabine (SEAMLESS)
Acute myeloid leukemia - cancer
Phase 1 data due 2019.
CYC065
Advanced cancers
Phase 1 initial data due 2019.
CYC065 + venetoclax
Chronic lymphocytic leukemia (CLL)
Phase 1b/2 initial data due 2019.
Sapacitabine in combination with olaparib
BRCA mutant breast cancer
Phase 1 initial data due 2019.
CYC140
Leukemias
Phase 1 data at AACR April 1, 2019. 2/20 partial responses (PRs).
Sapacitabine and seliciclib
BRCA mutant breast cancer
Phase 1/2 trial dosing has commenced - July 22, 2019.
Sapacitabine and Venetoclax
Relapsed or refractory Acute myeloid leukemia or myelodysplastic syndrome (MDS)

Latest News

  1. Edited Transcript of CYCC earnings conference call or presentation 13-Aug-19 8:30pm GMT
  2. Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
  3. The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
  4. The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
  5. Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
  6. Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
  7. Edited Transcript of CYCC earnings conference call or presentation 14-May-19 8:30pm GMT
  8. Some Cyclacel Pharmaceuticals (NASDAQ:CYCC) Shareholders Have Copped A 99% Share Price Wipe Out
  9. A Look At Benzinga Pro's Most-Searched Tickers For May 24
  10. Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results
  11. Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results
  12. Could Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) Investor Composition Influence The Stock Price?
  13. Edited Transcript of CYCC earnings conference call or presentation 27-Mar-19 8:30pm GMT
  14. Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
  15. Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  16. The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO
  17. Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action
  18. Cyclacel Provides Clinical Development Update and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
  19. Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
  20. Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results